Daprodustat
Jesduvroq (daprodustat) is a small molecule pharmaceutical. Daprodustat was first approved as Jesduvroq on 2023-02-01. It is used to treat anemia in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| hemic and lymphatic diseases | D006425 |
Trade Name
FDA
EMA
Jesduvroq
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Daprodustat
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| JESDUVROQ | GSK | N-216951 RX | 2023-02-01 | 5 products, RLD, RS |
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| jesduvroq | New Drug Application | 2023-02-01 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| anemia | EFO_0004272 | D000740 | D64.9 |
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
DAPRODUSTAT, JESDUVROQ, GLAXOSMITHKLINE | |||
| 2028-02-01 | NCE | ||
HCPCS
No data
Clinical
Clinical Trials
37 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anemia | D000740 | EFO_0004272 | D64.9 | 13 | 10 | 9 | — | — | 32 |
| Allergic bronchopulmonary aspergillosis | D001229 | EFO_0007140 | B44.81 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Peripheral vascular diseases | D016491 | EFO_0003875 | I73.9 | — | 1 | — | — | — | 1 |
| Operative surgical procedures | D013514 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | — | 1 |
| Wound healing | D014945 | GO_0042060 | 1 | — | — | — | — | 1 | |
| Tendon injuries | D013708 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | DAPRODUSTAT |
| INN | daprodustat |
| Description | Daprodustat, sold under the brand name Duvroq among others, is a medication that is used for the treatment of anemia due to chronic kidney disease. It is a hypoxia-inducible factor prolyl hydroxylase inhibitor. It is taken by mouth.
|
| Classification | Small molecule |
| Drug class | enzyme inhibitors: hypoxia-inducible factor (HIF) prolyl hydroxylase inhibitors |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | O=C(O)CNC(=O)C1C(=O)N(C2CCCCC2)C(=O)N(C2CCCCC2)C1=O |
Identifiers
| PDB | — |
| CAS-ID | 960539-70-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL3544988 |
| ChEBI ID | — |
| PubChem CID | 91617630 |
| DrugBank | DB11682 |
| UNII ID | JVR38ZM64B (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 250 documents
View more details
Safety
Black-box Warning
Black-box warning for: Jesduvroq
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
103 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more